Skip to content
10-Q

Quarterly Report

CYTOSORBENTS CORPORATION CTSO

0001104659-25-111389

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 10, 2025 62.8M sh
Shares Diluted Q3 2025 · Sep 30, 2025 62.75M sh
Shares Diluted Q3 2025 · Sep 30, 2025 62.04M sh
Shares Diluted Q3 2025 · Sep 30, 2024 54.45M sh
Shares Diluted Q3 2025 · Sep 30, 2024 54.34M sh
Capex Q3 2025 · Sep 30, 2025 $56K
Capex Q3 2025 · Sep 30, 2024 $215K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$7.55M
Operating Cash Flow restated Q3 2025 · Sep 30, 2024 −$12.09M
Long Term Debt Q3 2025 · Sep 30, 2025 $14.57M
Long Term Debt Q3 2025 · Dec 31, 2024 $14M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $7.54M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $3.28M
Stockholders Equity Q3 2025 · Sep 30, 2025 $9.02M
Stockholders Equity Q3 2025 · Jun 30, 2025 $11.59M
Stockholders Equity Q3 2025 · Dec 31, 2024 $11.11M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 $13.38M
Stockholders Equity restated Q3 2025 · Jun 30, 2024 $17.43M
Stockholders Equity restated Q3 2025 · Dec 31, 2023 $23.48M
Current Liabilities Q3 2025 · Sep 30, 2025 $10.11M
Current Liabilities Q3 2025 · Dec 31, 2024 $9.83M
Total Liabilities Q3 2025 · Sep 30, 2025 $36.73M
Total Liabilities Q3 2025 · Dec 31, 2024 $36.27M
Current Assets Q3 2025 · Sep 30, 2025 $21.31M
Current Assets Q3 2025 · Dec 31, 2024 $21.6M
Total Assets Q3 2025 · Sep 30, 2025 $45.75M
Total Assets Q3 2025 · Dec 31, 2024 $47.37M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.05
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.04
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$0.05
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.24
Eps Basic Q3 2025 · Sep 30, 2025 −$0.05
Eps Basic Q3 2025 · Sep 30, 2025 −$0.04
Eps Basic restated Q3 2025 · Sep 30, 2024 −$0.05
Eps Basic Q3 2025 · Sep 30, 2024 −$0.24
Sga Expense Q3 2025 · Sep 30, 2025 $8.61M
Sga Expense Q3 2025 · Sep 30, 2025 $26.21M
Sga Expense restated Q3 2025 · Sep 30, 2024 $8.26M
Sga Expense restated Q3 2025 · Sep 30, 2024 $26.1M
Net Income Q3 2025 · Sep 30, 2025 −$3.17M
Net Income Q3 2025 · Sep 30, 2025 −$2.7M
Net Income restated Q3 2025 · Sep 30, 2024 −$2.77M
Net Income restated Q3 2025 · Sep 30, 2024 −$13.15M
Operating Income Q3 2025 · Sep 30, 2025 −$2.86M
Operating Income Q3 2025 · Sep 30, 2025 −$10.36M
Operating Income restated Q3 2025 · Sep 30, 2024 −$4.83M
Operating Income restated Q3 2025 · Sep 30, 2024 −$13.06M
Gross Profit Q3 2025 · Sep 30, 2025 $6.67M
Gross Profit Q3 2025 · Sep 30, 2025 $19.69M
Gross Profit restated Q3 2025 · Sep 30, 2024 $5.26M
Gross Profit restated Q3 2025 · Sep 30, 2024 $18.63M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $2.82M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $8.14M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $3.36M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $7.81M